1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd.

6733.TWO
BioGend Therapeutics Co., Ltd.TW flagTaipei Exchange
26.25
TWD
+0.05
- -
3.27BMarket Cap

Total Valuation

BioGend Therapeutics Co., Ltd. carries a market capitalization of 3.27B, placing it among publicly traded companies globally. Its enterprise value stands at 4.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.27B
Enterprise Value4.42B

Share Statistics

BioGend Therapeutics Co., Ltd. currently has 124.74M shares outstanding.

Shares Outstanding124.74M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 30.57, and the price-to-book ratio stands at 6.46.

PE RatioN/A
PS Ratio30.57
PB Ratio6.46
P/TBV Ratio7.36
P/FCF Ratio-99.80
P/OCF Ratio-96.64

Enterprise Valuation

EV / Sales27.48
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

BioGend Therapeutics Co., Ltd. maintains a current ratio of 17.60, meaning it holds 17.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.87, indicating moderate leverage, while an interest coverage ratio of -835.11 demonstrates limited ability to service its debt obligations.

Current Ratio17.60
Quick Ratio14.32
Debt / Equity0.87
Debt / EBITDA-0.07
Interest Coverage-835.11

Financial Efficiency

Return on Equity (ROE)-9.69
Return on Assets (ROA)-9.00
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.43

Taxes

Income Tax-6.21M
Effective Tax RateN/A

Stock Price Statistics

BioGend Therapeutics Co., Ltd.'s stock has declined approximately -15.32258% over the past 52 weeks. The 50-day moving average sits at 29.71, while the 200-day moving average is 37.14.

Beta (5Y)N/A
52-Week Price Change-15.32258%
50-Day Moving Average29.71
200-Day Moving Average37.14
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, BioGend Therapeutics Co., Ltd. generated 160.67M in revenue and converted that into -77.74M in net income, yielding earnings per share of -0.67. EBITDA reached -98.54M, while operating income came in at -98.54M.

Revenue160.67M
Gross Profit116.32M
Operating Income-98.54M
Pretax Income-92.37M
Net Income-77.74M
EBITDA-98.54M
EBIT-98.54M
Earnings Per Share (EPS)-0.67

Balance Sheet

BioGend Therapeutics Co., Ltd. holds 517.90M in cash and equivalents against 6.58M in total debt, resulting in a net debt position of -217.90M. Total book value stands at 760.63M, with working capital of 600.27M providing operational flexibility.

Cash & Cash Equivalents517.90M
Total Debt6.58M
Net Debt-217.90M
Equity (Book Value)760.63M
Book Value Per Share5.93
Working Capital600.27M

Cash Flow

BioGend Therapeutics Co., Ltd. produced -50.83M in operating cash flow over the past twelve months. After subtracting -1.61M in capital expenditures, free cash flow totaled -52.44M - equivalent to -0.41 per share.

Operating Cash Flow-50.83M
Capital Expenditures-1.61M
Free Cash Flow-52.44M
FCF Per Share-0.41

Margins

BioGend Therapeutics Co., Ltd. operates with a gross margin of 72.39, reflecting its pricing power and cost economics. The operating margin of -61.33 and net profit margin of -48.38 provide insight into operational efficiency.

Gross Margin72.39
Operating Margin-61.33
Pretax Margin-57.49
Profit Margin-48.38
EBITDA Margin-61.33

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.06
FCF Yield-1.00

Stock Splits

BioGend Therapeutics Co., Ltd.'s most recent stock split took place on December 21, 2022 with a 1000:1013 split ratio.

Last Split Date12/21/2022
Split Ratio1000:1013

Scores

BioGend Therapeutics Co., Ltd. posts an Altman Z-Score of 50.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score50.88